Investment Thesis

DexCom, Inc. (DXCM) is a BUY at $62.25, as the market is currently undervaluing the company’s position as a leader in continuous glucose monitoring (CGM) technology. With the increasing prevalence of diabetes and the shift towards remote patient monitoring, DexCom is well-positioned to capture significant market share and grow its revenue streams substantially over the next several years. The company's innovative product pipeline, including the anticipated launch of the Dexcom G7, provides a compelling growth narrative that the market has yet to fully price in.

Competitive Moat

DexCom boasts a robust competitive moat characterized by strong intangible assets, including proprietary technology and regulatory approvals that create significant barriers to entry in the CGM market. The company's established brand recognition among healthcare providers and patients fosters high switching costs, as users are likely to remain loyal to a system that they trust for daily management of their diabetes. This advantage is expected to last over the next 5-10 years, although competition from Medtronic and Abbott, both of which have strong footholds in the diabetes management space, poses a threat to market share.

Growth Engine

Future revenue growth for DexCom is driven by an expanding total addressable market (TAM), anticipated at over $12 billion as diabetes rates continue to rise globally. The company is well-positioned to capitalize on this trend through geographic expansion, particularly in international markets where CGM penetration is still in its infancy. Additionally, the launch of new products, such as the Dexcom G7, will likely enhance pricing power and solidify DexCom’s market leadership. While organic growth will be the primary driver, potential acquisition opportunities in complementary technologies could further augment revenue.